Last reviewed · How we verify
XueBiJing Injection
XueBiJing Injection is a traditional Chinese medicine-derived herbal extract that modulates inflammatory and coagulation pathways to reduce sepsis-related organ dysfunction.
XueBiJing Injection is a traditional Chinese medicine-derived herbal extract that modulates inflammatory and coagulation pathways to reduce sepsis-related organ dysfunction. Used for Sepsis and septic shock, Systemic inflammatory response syndrome (SIRS), Disseminated intravascular coagulation (DIC) associated with sepsis.
At a glance
| Generic name | XueBiJing Injection |
|---|---|
| Also known as | Tianjin Chase Sun Pharmaceutical Co. LTD |
| Sponsor | Nanjing Medical University |
| Drug class | Herbal extract / Traditional Chinese Medicine |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Critical Care |
| Phase | FDA-approved |
Mechanism of action
The injection contains active compounds from Carthamus tinctorius, Salvia miltiorrhiza, and Paeoniae radix that work through multiple mechanisms including inhibition of pro-inflammatory cytokines (TNF-α, IL-6), reduction of endotoxin-induced coagulation cascade activation, and improvement of microcirculation. It is used primarily in sepsis management to attenuate systemic inflammatory response and prevent disseminated intravascular coagulation.
Approved indications
- Sepsis and septic shock
- Systemic inflammatory response syndrome (SIRS)
- Disseminated intravascular coagulation (DIC) associated with sepsis
Common side effects
- Allergic reaction / hypersensitivity
- Injection site reactions
- Gastrointestinal disturbance
Key clinical trials
- Effect of Xuebijing InjecTion on Outcomes in Sepsis Patients Under Real-World Conditions（EXIT-SEP REAL）
- Effect of Xuebijing in Alleviating Acute Kidney Injury After High-voltage Electrical Burns (NA)
- Novel Biomarkers Related Xuebijing Injection Improves Sepsis
- Additive Anti-inflammatory Action for Critically Ill Patients With Cardiovascular Surgery (Xuebijing) IV (NA)
- The Efficacy of Xuebijing Injection on Sepsis (PHASE4)
- Pharmacokinetics of XueBiJing in Patients With Sepsis (NA)
- Evaluate the Efficacy of Xuebijing Injection in Acute Exacerbations of COPD (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |